Compare
Abbott Laboratories vs LivaNova (ABT vs LIVN)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Abbott Laboratories (ABT) returned -11.7% and LivaNova (LIVN) +77.1%; so far this year the figures are -12.3% and +46.2%.
Abbott Laboratories is the larger company by market value, about 38.4 times the size of LivaNova.
On trailing earnings, ABT trades at 40.9 times and LIVN at 30.0 times.
Revenue grew +10.0% at ABT and +11.7% at LIVN over the last year.
ABT yields 2.29%. LIVN pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABT | LIVN | |
|---|---|---|
| Price | $109.93 | $89.99 |
| 1-day | -3.23% | -1.26% |
| YTD | -12.26% | +46.25% |
| 1 year | -11.73% | +77.11% |
| 3 years | +15.70% | +79.84% |
| Market cap | $190.4B | $5.0B |
| P/E | 40.9 | 30.0 |
| P/S | 3.95 | 3.29 |
| P/B | 3.73 | 3.61 |
| Revenue growth | +10.00% | +11.70% |
| EPS growth | -66.20% | — |
| Gross margin % | 56.9 | 67.8 |
| Net margin % | 9.7 | 13.0 |
| ROE % | 9.2 | 14.3 |
| Debt / equity | 0.61 | 0.22 |
| FCF yield % | 3.5 | 2.6 |
| Dividend yield % | 2.29 | — |
| Beta | 0.06 | 1.09 |
| RSI (14) | 58.5 | 66.9 |
| Technical rating |